1. In Vivo

Organs On Chips: The Silver Bullet Pharma Is Priming To Fire

 
• By Barnaby Pickering

In this two-part series, In Vivo will explore why organ on chip technology exists, the factors driving and limiting their application in drug development, and how companies can benefit from using them.    

Gun
• Source: Shutterstock

The cost of developing and taking a new drug to market can range from a hair under a billion to almost $3bn, with a study from the London School of Economics giving an average of $1.3bn.

It also takes typically between 10 and 15 years. Imjudo (tremelimumab-actl) for example, was approved in October 2022 after nearly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.